GLP-1 Cost Breakdown: Branded, Compounded, and 2026 Medicare

Even if a GLP-1 medication is right for you clinically, affordability is a separate hurdle. Monthly costs in the United States range from under $25 with good coverage to over $1,300 paying cash. Our GLP-1 cost calculator estimates your specific out-of-pocket cost based on medication, insurance type, and manufacturer savings programs. This post walks through the landscape.

Branded GLP-1 List Prices (as of early 2026)

These are typical U.S. list prices for a 28-day supply, per manufacturer disclosures:

• Wegovy (semaglutide 2.4 mg): approximately $1,350
• Ozempic (semaglutide, type 2 diabetes indication): approximately $950-1,000
• Zepbound (tirzepatide, weight management): approximately $1,060
• Mounjaro (tirzepatide, type 2 diabetes indication): approximately $1,070
• Saxenda (liraglutide): approximately $1,350

These are list prices. Actual cost to patients depends heavily on coverage.

Commercial Insurance

If your employer-sponsored or marketplace plan covers GLP-1s for weight management, out-of-pocket costs typically fall in the $25-$100/month range after deductible. However, many commercial plans:

• Require prior authorization with specific BMI and comorbidity documentation
• Mandate a documented lifestyle intervention period (often 3-6 months)
• Exclude weight management drugs entirely — they cover Ozempic for diabetes but not Wegovy for weight loss
• Impose step therapy — requiring failure of older medications first

Manufacturer savings cards (e.g., Novo Nordisk's NovoCare programs, Lilly's Zepbound Savings Card) can reduce commercial-insured copays to $25 in many cases, though eligibility rules and maximum savings caps apply.

Cash Pay and Direct Programs

In 2024-2025, both Lilly and Novo Nordisk launched direct-to-patient vial programs at lower price points for cash-paying patients. As of early 2026, typical pricing:

• Zepbound vials (Lilly Direct): around $349-$699/month depending on dose
• Wegovy direct (NovoCare): around $499/month for qualifying cash payers

These programs generally cannot be combined with insurance, and eligibility rules vary.

Compounded GLP-1s

Compounded semaglutide and tirzepatide surged during brand shortages in 2023-2024 through telehealth platforms and compounding pharmacies. The FDA removed both drugs from official shortage lists in late 2024/early 2025, which significantly changed the legal landscape:

• Once a drug is off the shortage list, 503A and 503B compounding of copies is generally not permitted
• Some platforms transitioned to personalized formulations (different salt forms, added B12, etc.) to remain legal
• The FDA has issued warnings about quality, dosing errors, and adverse events from some compounded products
• Compounded products are not FDA-approved, meaning the evidence base for any specific batch is weaker

Typical compounded pricing has ranged from $150-$500/month, but consumers should weigh cost against the regulatory and quality tradeoffs. Discuss with a licensed prescriber before using any compounded product.

Medicare and the 2026 Shift

Historically, Medicare has not covered medications "used for weight loss" — this is written into the original 2003 Medicare Modernization Act. As of 2026:

• GLP-1s prescribed for type 2 diabetes (Ozempic, Mounjaro) are covered by Medicare Part D
• GLP-1s prescribed purely for chronic weight management (Wegovy, Zepbound) historically have not been covered
• Following CMS guidance in 2024, coverage expanded when semaglutide 2.4 mg was approved for cardiovascular risk reduction in patients with established heart disease and obesity — this is covered under Medicare as a cardiovascular indication
• Broader weight-management coverage would require legislative change — proposals (TROA, etc.) remain under debate

The Inflation Reduction Act Medicare drug price negotiation process is also relevant — semaglutide is included in the 2027 negotiation class, which may affect Part D pricing starting in 2027-2028.

Medicaid

Medicaid coverage varies by state. Roughly 15 states cover GLP-1s for weight management as of early 2026, often with prior authorization requirements. Many more cover them for type 2 diabetes.

Cost-Saving Tactics

If you and your prescriber decide GLP-1 therapy is right for you, options to explore:

• Verify whether your plan's formulary lists Wegovy or Zepbound, and under which tier
• Check manufacturer savings programs for commercial-insured patients
• Consider manufacturer direct vial programs if paying cash
• Ask about dose-stepping strategies (staying on a lower maintenance dose if effective)
• Use a pharmacy discount tool to compare local cash prices
• Check whether your HSA/FSA covers out-of-pocket costs

What to Budget Long-Term

Weight-management GLP-1s are likely a chronic medication, not a short course. Annual costs can run from $600 (best-case insured) to $15,000+ (list price cash pay). Factor this into any decision, alongside the potential metabolic and cardiovascular benefits.

Next Steps

Use the GLP-1 cost calculator to estimate your monthly and annual out-of-pocket cost based on medication, dose, insurance status, and savings programs. Numbers change frequently, so verify with your pharmacy when a prescription is active. Speak with a licensed prescriber about whether GLP-1 therapy fits your health picture.